Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$77,142.00-1.60%ETH$2,258.53-1.35%GOLD$3,958.40-0.28%OIL$96.61+0.16%
Smart Investors Daily
SID Premium
WH

NASDAQ · WHWK

Whitehawk Therapeutics Inc

Healthcare · Biotechnology

$3.12

Down-$0.12 (-3.70%)

Updated Nov 3, 2026, 3:19 AM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
117.82M
P/E ratio
-16.58
Dividend yield
0.00%
52-week range
$1.97 – $5.50
Volume
216.91K
Avg. volume
1.77M

Price performance · WHWK

WHWK price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

WHWK closed at $3.12 after 21 trading sessions, down 15.68% for the selected period.

Last close
$3.12
Period change
-15.68%
Period low
$2.89
Period high
$3.70
Daily close
View OHLC price history
WHWK OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$3.27$3.295$3.08$3.12216.91K
Oct 30, 2026$3.29$3.37$3.20$3.24153.35K
Oct 29, 2026$3.48$3.51$3.245$3.30523.16K
Oct 28, 2026$3.30$3.46$3.20$3.46362.35K
Oct 27, 2026$3.15$3.335$3.1175$3.33290.06K
Oct 26, 2026$3.21$3.22$3.08$3.14235.79K
Oct 23, 2026$3.23$3.26$3.08$3.21222.61K
Oct 22, 2026$3.25$3.37$3.15$3.25261.7K
Oct 21, 2026$3.20$3.32$3.13$3.285279.99K
Oct 20, 2026$3.02$3.24$3.02$3.19417.76K
Oct 19, 2026$2.89$3.08$2.85$3.01520.16K
Oct 16, 2026$3.03$3.03$2.87$2.89273.98K
Oct 15, 2026$2.98$3.08$2.98$3.04337.4K
Oct 14, 2026$3.05$3.105$2.941$2.97510.06K
Oct 13, 2026$3.37$3.37$3.00$3.02461.73K
Oct 12, 2026$3.52$3.57$3.355$3.38222.05K
Oct 9, 2026$3.47$3.54$3.40$3.52320.26K
Oct 8, 2026$3.37$3.52$3.33$3.47248.6K
Oct 7, 2026$3.55$3.60$3.35$3.41435.72K
Oct 6, 2026$3.72$3.72$3.55$3.61468.16K
Oct 5, 2026$3.73$3.75$3.61$3.70289.14K

Latest WHWK news

The latest Smart Investors Daily articles mentioning WHWK.

Stock researchCompany · Overview

WHWK research

Overview

Company profile and research snapshot.

Company profile

Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
WHWK recent ratings
DateFirmRatingTarget
Oct 1, 2026StifelBuy—
Jul 13, 2026Leerink PartnersOutperform—
Jun 25, 2026B. Riley SecuritiesBuy—
Apr 16, 2026CitizensMarket Outperform—
Dec 22, 2025Jones TradingBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 7, 2026

Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development

Veeva Systems (NYSE: VEEV) today announced that more than 175 emerging biotechs are establishing a technology foundation with Veeva Basics. Biotechs are launching pre-configured and pre-validated Veeva Basics applications in weeks, adding systems that can scale as they move from startup to commercialization. Veeva Basics delivers unified, end-to-end applications for clinical, regulatory, quality, medical, and commercial, enabling high-growth companies to speed innovation while saving time, effor

Yahoo · Oct 1, 2026

Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026

Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of two real-world analyses supporting mucin 16 (MUC16) as a durable therapeutic target and potential prognostic biomarker in ovarian cancer. These data will be presented at the International Gynecologic Cancer Society (IGCS) Annual Gl

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By